Sign in
Taking peoplePhase 3

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

Key facts

Who runs it
CSL Behring
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
90 people, planned
Started
1 Oct 2024
Expected to end
30 Jun 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • CSL511 Fibrinogen concentrate (human)
  • Cryoprecipitate
Record updated
13 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • • Aged >= 18 years at the time of providing written informed consent
  • • Diagnosis of PMP requiring CRS with HIPEC
  • • Bleeding risk: Predicted intraoperative blood loss of >=2L, assessed within 60 and 100 mins after start of study surgery (assessment made before 2 L of blood is lost)

Who cannot take part

  • • Myocardial infarction, acute coronary syndrome, or stroke within 2 months before study surgery
  • • Clopidogrel or ticagrelor administration within 5 days before study surgery
  • • Prasugrel administration within 7 days before study surgery
  • • Oral factor Xa inhibitor administration within 2 days before study surgery
  • • Glycoprotein IIb / IIIa antagonist administration within 24 hours before study surgery
  • • Oral direct thrombin inhibitor administration within 3 days before study surgery
  • • Vitamin K antagonists within 5 days before study surgery
  • • Confirmed or suspected congenital or acquired coagulation disorder or a prothrombotic disorder
  • • Known history of chronic hepatitis

This trial is currently available in United Kingdom.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a phase 3, prospective, single center, randomized, open label, controlled, parallel arm, interventional study to investigate the efficacy and safety of CSL511, in participants undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP) with predicted intraoperative blood loss of greater than or equal to (>=) 2 liter (L). Eligible participants will be randomized in a 1:1 ratio to 1 of 2 treatment arms, to receive CSL511 or cryoprecipitate.

The 2 groups in the trial

  • CSL511Treatment being tested

    Treatment: CSL511 Fibrinogen concentrate (human)

  • CryoprecipitateExisting treatment, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3, Single-center, Randomized, Controlled Clinical Study to Investigate the Efficacy of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery
Record updated
13 October 2026